Oral Solid Dosage Contract Manufacturing Global Market Report 2024

The oral solid dosage contract manufacturing market size has grown strongly in recent years. It will grow from $36.7 billion in 2023 to $39.39 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be linked to the expanding global population, the widespread occurrence of chronic diseases, and an increased emphasis on research and development.

The oral solid dosage contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $52.94 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The projected growth in the forecast period is due to more pharmaceutical companies outsourcing, progress in drug delivery technology, and heightened drug development activities. Key trends expected in this period include advancements in drug delivery technology, the integration of 3D printing, and progress in controlled-release technologies.

The surge in demand for generic drugs is anticipated to drive the growth of the oral solid dosage contract manufacturing market in the coming years. Generic drugs are medications that are bioequivalent to brand-name drugs in dosage, strength, safety, performance, quality, and intended use. The increasing demand for generic drugs is fueled by factors such as patent expirations, cost containment initiatives, regulatory incentives, and efforts to expand access to healthcare. Oral solid dosage contract manufacturing plays a pivotal role in facilitating the production and distribution of generic drugs by leveraging the capabilities of contract manufacturers to enhance operational efficiency, reduce costs, ensure high-quality production, and expedite the introduction of products to the market. For example, in 2022, the Food and Drug Administration (FDA) estimated that 91% of all prescriptions in the USA were filled with generic drugs, with over 32,000 generic drugs approved by the FDA. Consequently, the demand for generic drugs propels the growth of the oral solid dosage contract manufacturing market.

Key players in the oral solid dosage contract manufacturing market are concentrating on developing innovative solutions, such as continuous manufacturing lines, to fortify their position in the market. A continuous manufacturing line refers to a production facility or system that employs continuous manufacturing processes to produce pharmaceuticals or other products. For instance, in January 2023, WuXi STA, a pharmaceutical company based in China, inaugurated its first continuous manufacturing line for oral solid pharmaceutical products. This state-of-the-art facility represents a significant advancement in pharmaceutical production, harnessing continuous manufacturing principles to enhance efficiency, quality, and flexibility in drug manufacturing processes. This enhanced agility streamlines production timelines and minimizes downtime, ultimately expediting the delivery of essential medications to patients.

In August 2022, Catalent Inc., a US-based pharmaceutical company, completed the acquisition of Metrics Contract Services for $475 million. Through this acquisition, Catalent seeks to broaden its capabilities in the development and manufacturing of oral solid dosage forms. Metrics Contract Services is a US-based full-service contract development and manufacturing organization (CDMO) specializing in oral dosage forms.

Major companies operating in the oral solid dosage contract manufacturing market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Siemens Healthineers AG, Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under the CordenPharma brand, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation.

Asia Pacific was the largest region in the oral solid dosage contract manufacturing market in 2023. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral solid dosage contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oral solid dosage contract manufacturing involves outsourcing the production of oral solid dosage forms of pharmaceuticals to third-party manufacturers. This strategy enables pharmaceutical companies to concentrate on their core activities, such as research, development, and marketing, while utilizing the expertise and capabilities of contract manufacturing organizations (CMOs) to efficiently produce high-quality oral solid dosage pharmaceuticals.

The main product types in oral solid dosage contract manufacturing include tablets, capsules, powders, granules, and other forms. Tablets are small, solid masses of medicine containing an active drug and excipients. The services offered encompass drug product development, fill-finish product manufacturing, API manufacturing, packaging and labeling, and other applications. The therapeutic areas covered include oncology, cardiovascular diseases, metabolic disorders, neurological disorders, infectious diseases, gastrointestinal diseases, and other therapeutic areas. The end users of these services are large companies, as well as medium and small companies.

The oral solid dosage contract manufacturing market research report is one of a series of new reports that provides oral solid dosage contract manufacturing market statistics, including oral solid dosage contract manufacturing industry global market size, regional shares, competitors with a oral solid dosage contract manufacturing market share, detailed oral solid dosage contract manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the oral solid dosage contract manufacturing industry. This oral solid dosage contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral solid dosage contract manufacturing market consists of revenues earned by entities by providing services such as formulation development, analytical and stability testing, and quality assurance and control. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral solid dosage contract manufacturing market also consists of sales of orally disintegrating tablets (ODTS), lozenges, and chewing gums. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.